Zealand Pharma

Zealand Pharma Presents Data from Phase 1 Trial of Dapiglutide at the 82nd Annual American Diabetes Association Scientific Sessions and Announces Dapiglutide to Move into Phase 2 Trial for Obesity

Retrieved on: 
Monday, June 6, 2022
Biomarker, Advertising, AES, Intellectual property, Research, Drug nomenclature, Boehringer Ingelheim, ADA, Pharmacokinetics, Plasma, Weight loss, Failure, Half-life, American Diabetes Association, Nasdaq, Metabolism, Patient, Private Securities Litigation Reform Act, Malnutrition, AstraZeneca, COVID-19, Obesity, DK, Lists of diseases, Degenerative disease, Overweight, Safety, Pharmaceutical industry, Zealand Pharma

Dapiglutide also demonstrated an acceptable safety profile and was found to be appropriate for once weekly injection.

Key Points: 
  • Dapiglutide also demonstrated an acceptable safety profile and was found to be appropriate for once weekly injection.
  • Multiple doses of dapiglutide were well-tolerated and the safety profile as expected for GLP-1 and GLP-2 receptor agonists.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines.
  • Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.

Zealand Pharma completes registration of capital increase

Retrieved on: 
Friday, June 3, 2022
ACT, Mission statement, AS, NOT, FINANCIAL, Failure, Private, BY, Sale, AstraZeneca, Finance, COVID-19, Financial Services and Markets Act 2000, ANY, Association, Advertising, Intellectual property, AFRICA, Order, Income, Structured Product Labeling, European Union (Withdrawal) Act 2018, EEA, DKK, United Kingdom, THE, Boehringer Ingelheim, FOR, OF, Patient, Nasdaq Copenhagen, Private Securities Litigation Reform Act, Research, Nasdaq, ISIN, OR, Prospectus, Zealand Pharma, District, Financial services, Private placement, Person, Security (finance), Financial adviser, Life insurance, Cryptocurrency, Property management, EU

3/2022, Zealand Pharma A/S ("Zealand") announces that it has today, as part of completion of a directed issue and private placement (the "Private Placement"), registered with the Danish Business Authority, the capital increase of DKK 2,892,368, divided into 2,892,368 ordinary shares (the "New Shares").

Key Points: 
  • 3/2022, Zealand Pharma A/S ("Zealand") announces that it has today, as part of completion of a directed issue and private placement (the "Private Placement"), registered with the Danish Business Authority, the capital increase of DKK 2,892,368, divided into 2,892,368 ordinary shares (the "New Shares").
  • The amendments to Zealand's articles of association required by the capital increase have been registered today with the Danish Business Authority.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines.
  • All such forward-looking statements speak only as of the date of this press release and are based on information available to Zealand Pharma as of the date of this release.

Zealand Pharma to Participate in Upcoming Investor Conferences

Retrieved on: 
Friday, June 3, 2022
Nasdaq, Jefferies, DK, Patient, Webcast, Company, AstraZeneca, Boehringer Ingelheim, Zealand Pharma, Fine chemical, Online shopping

Copenhagen, DK and Boston, MA, U.S. June 3, 2022 Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.

Key Points: 
  • Copenhagen, DK and Boston, MA, U.S. June 3, 2022 Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
  • 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines,today announced that the company will participate in the following investor conferences in June:
    A live webcast of the Jefferies presentation will be available on the "Events & Presentations" page in the Investor section of the Company's website at https://www.zealandpharma.com/events-presentations .
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines.
  • Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA).

Zealand Pharma Announces Appointment of David M. Kendall, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, June 2, 2022
Faculty, VP, Leadership, Eli Lilly, University of Minnesota Medical School, Advertising, Company, Intellectual property, Research, Boehringer Ingelheim, University, St. Olaf College, Failure, American Diabetes Association, Medicine, International Diabetes Center at Park Nicollet, Nasdaq, MannKind Corporation, Patient, Private Securities Litigation Reform Act, Diabetes, AstraZeneca, COVID-19, Zealand Pharma, DK, Medical Affairs Bureau, Lists of diseases, Education, Pharmaceutical industry

Zealand Pharma Announces Appointment of David M. Kendall, M.D., as Chief Medical Officer

Key Points: 
  • Zealand Pharma Announces Appointment of David M. Kendall, M.D., as Chief Medical Officer
    Copenhagen, DK and Boston, MA, U.S. June 2, 2022 Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
  • Dr. Kendalls expertise will be critical to Zealand in his new role as Chief Medical Officer, particularly as we refocus efforts on advancing our unique research and development pipeline, said Adam Steensberg, Chief Executive Officer, Zealand Pharma.
  • It is an honor to take on this role during such an exciting and transformative time for Zealand, said Dr. Kendall, newly appointed Chief Medical Officer, Zealand Pharma.
  • He has served as Chief Medical Officer for MannKind Corporation, VP - Medical Affairs and Distinguished Medical Fellow at Eli Lilly and Company and as Chief Scientific and Medical Officer for the American Diabetes Association.

Zealand Pharma announces directed issue and private placement corresponding to approx. 6.6 % of existing share capital

Retrieved on: 
Wednesday, June 1, 2022
ACT, Private placement, Mission statement, AS, FINANCIAL, Failure, Private, BY, Sale, AstraZeneca, Finance, COVID-19, Authority, Financial Services and Markets Act 2000, ANY, Association, Advertising, Intellectual property, AFRICA, Order, Income, Structured Product Labeling, European Union (Withdrawal) Act 2018, EEA, DKK, United Kingdom, THE, Boehringer Ingelheim, OF, Pharma, Patient, Nasdaq Copenhagen, Private Securities Litigation Reform Act, Research, News, Nasdaq, ISIN, OR, Prospectus, Zealand Pharma, District, Financial services, Person, Fine chemical, Security (finance), Pension fund, Financial adviser, Life insurance, Cryptocurrency, Property management, EU

Zealand Pharma announces directed issue and private placement corresponding to approx.

Key Points: 
  • Zealand Pharma announces directed issue and private placement corresponding to approx.
  • 6.6% of Zealand's currently registered share capital, to certain reputable institutional shareholders (the "Private Placement").
  • The subscription price equals the price for Zealand's shares quoted on Nasdaq Copenhagen at the time the Private Placement was made.
  • Danske Bank A/S and Nordea Danmark, Filial af Nordea Bank Abp, Finland are acting as joint global coordinators for the Private Placement.

Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities

Retrieved on: 
Tuesday, May 31, 2022
Diabetes, Hypoglycemia, Patient, Boehringer Ingelheim, Person, DK, Nasdaq, Adult, AstraZeneca, Zealand Pharma, Pharmaceutical industry

Copenhagen, DK and Boston, MA, May 31, 2022 Zealand Pharma A/S (Zealand) (Nasdaq: ZEAL) (CVR-no.

Key Points: 
  • Copenhagen, DK and Boston, MA, May 31, 2022 Zealand Pharma A/S (Zealand) (Nasdaq: ZEAL) (CVR-no.
  • 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it has received information on transactions in Zealand shares or related securities by persons discharging managerial responsibilities.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines.
  • All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

Zealand Pharma Announces Multiple Presentations at the 82nd Annual American Diabetes Association Scientific Sessions, Including Initial Clinical Data on GLP-1/GLP-2 Dual Agonist Dapiglutide

Retrieved on: 
Tuesday, May 31, 2022
Well, People, Oxyntomodulin, Safe Medical Device Amendments of 1990, Private Securities Litigation Reform Act, IIT, Fibrillation, Nasdaq, American Diabetes Association, 2021 Essex County Council election, Hypoglycemia, Patient, Drug nomenclature, Obesity, DK, Treatment, Lists of diseases, Animal Health, Time, Half-life, Human, COVID-19, Failure, GCGR, Research, ADA, Glucagon-like peptide-1 receptor, Plasma, Peptide, Intellectual property, Public, CDT, Safety, Biomarker, Solubility, Steno Diabetes Center, Advertising, Boehringer Ingelheim, Animal, Randomness, Weight loss, AstraZeneca, Zealand Pharma, Pharmaceutical industry, Fine chemical, Flour

Zealand Pharma Announces Multiple Presentations at the 82nd Annual American Diabetes Association Scientific Sessions, Including Initial Clinical Data on GLP-1/GLP-2 Dual Agonist Dapiglutide

Key Points: 
  • Zealand Pharma Announces Multiple Presentations at the 82nd Annual American Diabetes Association Scientific Sessions, Including Initial Clinical Data on GLP-1/GLP-2 Dual Agonist Dapiglutide
    Copenhagen, DK and Boston, MA, U.S. May 31, 2022 Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
  • Zealand Pharma has two oral presentations, including Phase 1 clinical data demonstrating significant weight loss with Zealands dapiglutide, a novel GLP1/GLP2 dual agonist and preclinical data on the antidiabetic potential of the companys long-acting amylin analogue ZP8396.
  • Two additional abstracts include study results from a Zealand supported, investigator-initiated trial (IIT) with dasiglucagon led by investigators from the Steno Diabetes Center.
  • Additionally, Boehringer Ingelheim will have a poster presentation with preclinical data on the dual glucagon and glucagon-like peptide-1 receptor (GCGR/GLP-1R) agonist BI 456906 co-invented with Zealand Pharma, for the treatment of obesity.

Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities

Retrieved on: 
Wednesday, May 25, 2022
Diabetes, Hypoglycemia, Patient, Boehringer Ingelheim, Person, DK, Nasdaq, Adult, AstraZeneca, Zealand Pharma, Pharmaceutical industry

Copenhagen, DK and Boston, MA, May 25, 2022 Zealand Pharma A/S (Zealand) (Nasdaq: ZEAL) (CVR-no.

Key Points: 
  • Copenhagen, DK and Boston, MA, May 25, 2022 Zealand Pharma A/S (Zealand) (Nasdaq: ZEAL) (CVR-no.
  • 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it has received information on transactions in Zealand shares or related securities by persons discharging managerial responsibilities.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines.
  • All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)  

Retrieved on: 
Thursday, May 19, 2022
Royal commission, Congenital hyperinsulinism, Medicine, Private Securities Litigation Reform Act, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, European Commission, Nasdaq, Patient, Hypoglycemia, SOC, Dasiglucagon, DK, IV, COVID-19, Failure, Marketing, Research, FDA, Intellectual property, Program, DEKA, Standard of care, Advertising, NDA, Boehringer Ingelheim, Pancreatectomy, AstraZeneca, Zealand Pharma, Medical device, Pharmaceutical industry, CHI

20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced positive top-line results from its second Phase 3 clinical trial of dasiglucagon in pediatric patients with congenital hyperinsulinism (CHI).

Key Points: 
  • 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced positive top-line results from its second Phase 3 clinical trial of dasiglucagon in pediatric patients with congenital hyperinsulinism (CHI).
  • The Phase 3 program for dasiglucagon constitutes the largest clinical development program ever conducted in CHI.
  • In total, 42 of 44 participants enrolled across the dasiglucagon CHI Phase 3 clinical programs continued into the ongoing safety extension trial.
  • We are extremely pleased with the top-line results from our second Phase 3 study of dasiglucagon for the treatment of infants with CHI.

MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma

Retrieved on: 
Tuesday, May 17, 2022
Diabetes, Physician, Company, Doctor of Pharmacy, Annual report, Nasdaq, Patient, Form 10-K, MannKind Corporation, FDA, Life, Professional corporation, Acquisition, SEC, GLOBE, MD, Pharmacy, Pharmaceutical industry, Risk management, Zealand Pharma

The acquisition of V-Go allows MannKind to expand its portfolio and strengthen its commitment to providing innovative mealtime diabetes solutions.

Key Points: 
  • The acquisition of V-Go allows MannKind to expand its portfolio and strengthen its commitment to providing innovative mealtime diabetes solutions.
  • MannKind is passionate about being a leader in mealtime control to address this unmet need within the diabetes community, said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation.
  • V-Go is a once-daily, wearable, insulin delivery device that helps provide blood sugar control for everyday lifestyles.
  • MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases.